PLETTERS

An unusual case of “giant cell arteritis”
J Lim, R Ramachandran, R Madhok, H Capell


Cholesterol emboli syndrome (CES) can be confused with a small vessel vasculitis but it is unusual for it to be mistaken for giant cell arteritis. We report a patient with temporal headaches, transient visual loss, and raised inflammatory indices, which led to an initial diagnosis of giant cell arteritis, but in whom CES was the eventual explanation.

CASE REPORT
A 64 year old woman with treated hypertension who smoked was referred with a 1 year history of left sided temporal headaches and pain in the proximal lower limbs. The headaches were intermittent but were increasing in frequency and intensity. She also described two episodes of blurred vision of short duration in the left eye. There were no other associated neurological symptoms. She gave a history of Raynaud’s phenomenon in both hands and worsening activities of daily living limited by fatigue.

She was overweight with a body mass index of 27 kg/m²; there were no mucocutaneous abnormalities. The temporal arteries were not palpable and a fundoscopic examination was normal. All peripheral pulses were present and there were no nailfold capillary changes. She had no tender or swollen joints; there was functional range of movement in axial and peripheral joints.

Laboratory investigations showed haemoglobin of 127 g/l, a white cell count of 10.7×10⁹/l with a normal differential, and 625×10⁹/l platelets. The erythrocyte sedimentation rate (ESR) was 60 mm/1st h and C reactive protein (CRP) 290 mg/l. She had a serum urea and creatinine of 5.5 mmol/l and 96 mU/ml, respectively, with normal urine microscopy. The liver enzymes were not raised. Rheumatoid factor and antinuclear factor were absent.

Based on her symptoms and raised inflammatory indices, a provisional diagnosis of temporal arteritis was made and treatment was started with prednisolone 50 mg daily. A left temporal artery biopsy showed atherosclerotic change without evidence of granulomatous inflammation. This negative result was attributed to sampling error.

She continued to have multiple episodes of transient monocular visual loss which were highly suggestive of amaurosis fugax. She had also developed more troublesome acrocyanosis, livedo reticularis, and had a blood pressure of 190/83. The neurological examination was normal and there were no audible carotid bruits. Urine analysis remained negative, with normal renal function and inflammatory indices, but the total cholesterol was raised at 7.4 mmol/l. Her ECG did not suggest a rhythm abnormality. Formal fundoscopic examination showed a cholesterol crystal lodged in a vessel with background atherosclerotic change (fig 1). Carotid Doppler ultrasonography showed echolucent atherosclerotic plaques with a lumen diameter of 2 mm, while trans-oesophageal echocardiography did not show any mural thrombus or plaques in the aortic arch. A statin and aspirin were added to her drug treatment. Prednisolone was tapered over 2 weeks and stopped. When reviewed she denied further visual symptoms or other evidence of systemic emboli.

DISCUSSION
CES arises because of distal showering of cholesterol crystals into the circulation from atheromatous plaques. Panum first described this phenomenon in 1862. The presence of an aortic aneurysm, angioplasty, major vessel surgery, and use of thrombolytic and anticoagulating agents further increases the likelihood of CES.

Our patient fulfilled three of the five classification criteria for giant cell arteritis formulated by the American College of Rheumatology. Furthermore, she had visual symptoms, myalgia, and a raised acute phase response, which further supported our diagnosis. But the partial response to corticosteroids, worsening visual symptoms, emergence of livedo reticularis, and acrocyanosis suggested an alternative explanation. Fundoscopic evidence of cholesterol emboli confirmed the occurrence of CES.

Pseudovasculitis is sometimes used to describe the occurrence of fever, myalgia, leucocytosis, and raised ESR and CRP due to cholesterol emboli. The acute phase response is thought to arise from the inflammation provoked by the presence of cholesterol emboli in the vessel lumen and may explain the partial response to corticosteroids. No treatment has been proved to improve the outcome of CES, though statins have the theoretical benefit of plaque stabilisation.

Interestingly, there is only one other case report of CES masquerading as giant cell arteritis (PubMed search4). This is surprising given the similarity in the signs and symptoms of the two conditions and that both occur more frequently in those over the age of 50. Our case serves as reminder that not all older patients with headaches, myalgia, visual symptoms, and high ESR have giant cell arteritis. CES should be considered in those with a negative biopsy, a poor clinical response to corticosteroids, and risk factors for atherosclerosis.

Authors’ affiliations
J Lim, R Ramachandran, R Madhok, H Capell, Centre of Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, Scotland, UK

Figure 1 Retinal photograph showing a cholesterol crystal lodged in the small vessel of the retina (arrow).

References

Figure 1 Retinal photograph showing a cholesterol crystal lodged in the small vessel of the retina (arrow).
Visceral leishmaniasis resembling systemic lupus erythematosus

P V Voulgari, G A Pappas, E N Liberopoulos, M Elisaf, F N Skopouli, A A Drosos


Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown aetiology. B cell hyperactivity with production of multiple autoantibodies is the hallmark of the disease. On the other hand, such polyclonal B cell activation may occur in chronic infectious diseases. In this report we present a patient with visceral leishmaniasis who was diagnosed as having SLE and we discuss the clinical and laboratory findings which may discriminate between these two entities.

CASE REPORT

A 50 year old man presented in October 2001 with arthralgias, fatigue, weight loss, and low grade fever. Laboratory evaluation revealed haemoglobin 110 g/l, white blood cells 3.9×10⁹/l with normal differential count, platelets 90×10⁹/l, and erythrocyte sedimentation rate (ESR) 50 mm/1st h.

He was admitted to the hospital where physical examination disclosed mild splenomegaly. A laboratory investigation confirmed anaemia, leucopenia, and thrombocytopenia, increased ESR and C reactive protein (CRP) (table 1). Renal, liver and thyroid function tests, as well as urine analysis were within normal limits or negative. Serum electrophoresis showed moderate diffuse hypergammaglobulinaemia with no monoclonal bands. A stool specimen for occult blood was negative. Repeated blood, urine, throat, and bone marrow cultures were negative. Serological tests for viral hepatitis B and C, cytomegalovirus, Epstein-Barr virus, and human immunodeficiency virus, as well as for toxoplasma and brucella infections were negative. Immunological tests showed positive antinuclear antibodies (ANA) at a titre of 1/1280 with a fine speckled pattern, positive IgM rheumatoid factor at a titre of 1/640, positive anti-Sm antibodies, positive Venerale Disease Research Laboratory (VDRL) test and positive lupus anticoagulant test (table 1). A chest radiograph was normal and a purified protein derivative test was negative. Finally, bone marrow biopsy showed no abnormalities. A diagnosis of SLE was made.

Two months later, the patient experienced high spike fever, fatigue, and weight loss. He was treated with small doses of steroids without improvement and he was admitted for further evaluation. Physical examination showed a body temperature of 39°C. The patient was sweating, anxious, and pallid. The rest of physical examination disclosed moderate splenomegaly. A computed tomography scan of the abdomen confirmed the presence of splenomegaly. Laboratory and immunological tests were similar to those done previously (table 1). However, a high titre of antibodies directed against Leishmania donovani was detected (1/1280 by immunofluorescence assay). A repeated bone marrow biopsy disclosed the presence of parasites in the macrophages (fig 1). Sodium antimony gluconate was given intramuscularly for 4 weeks, with excellent results.

DISCUSSION

The haematological abnormalities of SLE include haemolytic anaemia, leucopenia or lymphopenia, and thrombocytopenia, due to the presence of autoantibodies directed against erythrocytes, leucocytes, and platelets. The diagnosis of SLE requires four or more of the American College of Rheumatology criteria. In our patient the diagnosis of SLE was based on the following criteria: arthralgias, haematological abnormalities, positive ANA, and positive VDRL and anti-Sm antibodies. However, this patient also had splenomegaly and high titres of CRP. Splenomegaly is not a common sign of SLE, unless there is lymphoma development or concurrent infection. High titres of CRP are not a common laboratory finding in SLE, unless a concurrent infection occurs. However, high titres of CRP in lupus have been associated with symmetrical polyarthritis and the presence of pleurisy.

Table 1 Laboratory and immunological features

<table>
<thead>
<tr>
<th>Variables</th>
<th>October 2001</th>
<th>February 2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemoglobin (g/l)</td>
<td>110</td>
<td>105</td>
</tr>
<tr>
<td>White blood cells (×10⁹/l)</td>
<td>3.9</td>
<td>3.65</td>
</tr>
<tr>
<td>Platelets (×10⁹/l)</td>
<td>90</td>
<td>75</td>
</tr>
<tr>
<td>ESR (mm/1st h)</td>
<td>50</td>
<td>65</td>
</tr>
<tr>
<td>C reactive protein (mg/l)</td>
<td>56</td>
<td>75</td>
</tr>
<tr>
<td>Antinuclear antibodies (titre)</td>
<td>1/1280</td>
<td>1/1280</td>
</tr>
<tr>
<td>IgM rheumatoid factor (titre)</td>
<td>1/640</td>
<td>1/640</td>
</tr>
<tr>
<td>Anti-Sm antibodies</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>VDRL test</td>
<td>Positive</td>
<td>Not done</td>
</tr>
<tr>
<td>Lupus anticoagulant</td>
<td>Positive</td>
<td>Not done</td>
</tr>
<tr>
<td>Direct Coombs test</td>
<td>Positive</td>
<td>Negative</td>
</tr>
</tbody>
</table>

VDRL, Venerale Disease Research Laboratory.
Neurovascular mechanisms as a possible cause of remission of rheumatoid arthritis in hemiparetic limbs

G Keyszer, Th Langer, M Kornhuber, B Taute, G Homeff

In patients with rheumatoid arthritis (RA), ischaemic stroke frequently leads to an unexplained remission of the arthritis in the paretic limb. Here we present two cases which suggest that neurovascular mechanisms contribute to the asymmetry of inflammation by impairing the microcirculation in the paretic extremity.

**CASE REPORTS**

A 47 year old man developed RA in 1988. In 1990, he had an apoplectic insult, resulting in a complete, left sided hemiplegia. The right hand had a marked ulnar drift of the metacarpophalangeal (MCP) joints and an inflamed wrist with impaired motion, whereas the left hand showed no inflammation or deformity. An x-ray analysis of the right hand demonstrated carpal ankylosis and subluxation and erosion of all MCP joints. The left hand showed no erosive changes (fig 1A). Thermal imaging indicated marked temperature differences between both hands, most obvious at the wrists (fig 1B). Duplex sonography measured no detectable flow of the left radial artery. Electrophysiological investigation suggested demyelination that was slightly more pronounced on the paralytic side. The sympathetic skin response was negative.

The second case involved a 66 year old woman who had had RA since 1982. In 1988 she had an ischaemic stroke with right sided hemiparesis that later recovered, leaving merely somewhat diminished muscle strength and minor hyperaesthesia. The left wrist and all MCP joints had active arthritis, whereas on the right, only two MCP joints were inflamed. An x-ray analysis of the left hand disclosed carpal ankylosis, subluxation of all MCP joints, and erosions of all carpometacarpal (CMC), MCP, and proximal interphalangeal

**REFERENCES**

PIP joints. The right hand showed erosions at one CMC joint and one PIP joint only. Thermal imaging showed a decreased skin temperature on the left wrist. However, the difference was not as marked as in the first patient. Interleukin 2, 4, 5, 10, tumour necrosis factor α, and interferon γ were determined in plasma on three consecutive days for each arm separately, but did not show differences between the two sides. Duplex sonography and electrophysiological investigation showed no asymmetry.

DISCUSSION
The mechanism by which RA is modified by hemiparesis is poorly understood. Our observations suggest a link between the severity of paralysis and the extent of the remission of arthritis. This agrees with biopsy findings of a mild arthritis in a knee joint after the restoration of the motor function of the paralysed leg.1

It has been suggested that the remission of arthritis after paralysis is due to the absence of mechanical factors.2 However, rheumatoid vasculitis and scleroderma can develop on the non-paralysed side after hemiplegia,3 arguing against a mechanical link.

A role for the autonomic nervous system in inflammation has been discussed.4 Neurogenic peptides might contribute to the asymmetry of arthritis after stroke.5 In patients with RA with hemiplegia, there are no reports of different concentrations of neurogenic peptides on the two sides. In our patients, measurement of the sympathetic skin response did not suggest differences in autonomous innervation between the sides.

Another mechanism by which neurogenic factors might contribute to the asymmetry of arthritis is an impaired perfusion of the paralysed limb.6 Our patients are the first in whom the skin temperature and the limb perfusion was assessed quantitatively. In our first case, no flow signal of the radial artery was detectable. The marked difference in skin temperature also indicates impaired microcirculation in both patients. Significantly, this phenomenon was most obvious in the patient with complete paralysis. Changes in skin temperature frequently occur after hemiplegic stroke.7 This
Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor α as a new therapeutic option

A K Tausche, K Richter, A Gräßler, S Hänsel, B Roch, H E Schröder

We report the case of a 53 year old man with a history of gouty arthritis extending over several years. He had had an acute kidney failure 2 years previously because of nephrolithiasis with urate calculi.

CASE REPORT
At the first consultation the patient had severe painful gouty arthritis (three to four attacks a week) of the joints of the big toes, the ankle joints, and different finger joints as well as in joints of the hands, shoulders, and knees. In addition to the polyarticular joint manifestation, multiple gouty tophi were present in the subcutaneous tissue (fig 1).

The medical history of the patient showed he had arterial hypertension and hypertriglyceridaemia. He consumed 20–25 units of alcohol weekly. Standard treatment was impractical because the patient had developed incompatibility with allopurinol and benz bromarone, which manifested as diarrhoea and a generalised exanthema.

Laboratory tests showed a raised white blood cell count (WBC) of 9.4 x 10^9/l; an erythrocyte sedimentation rate (ESR) 55 mm/1st h, C reactive protein (CRP) 61.0 mg/l, serum uric acid 580 μmol/l. Transaminases were normal apart from a γ-glutamyltransferase of 282 U/l. Clinical examination, including cardiovascular and respiratory systems, an electrocardiogram, and a chest radiograph were normal. Abdominal ultrasound was also normal apart from showing hepatomegaly. The radiographs of all symptomatic joints showed impressive signs of destructive gouty arthritis (fig 2).

Despite exhaustive treatment with colchicine, diclofenac, methylprednisolone, and opioids, the arthritis attacks did not improve considerably (table 1).

After obtaining the latest detailed information about the patient and his informed consent, treatment with etanercept (Enbrel) 25 mg subcutaneously twice weekly was started. As table 1 shows the frequency (gouty attacks per week) and the intensity (number of painful joints) of the gouty arthritis decreased considerably after four injections of etanercept. Laboratory tests showed a noticeable decrease of the inflammatory parameters. Decreased temperature on the intensity (number of painful joints) of the gouty arthritis impressively reduced the clinical manifestations of gout. WBC of 7.4 x 10^9/l; ESR 6 mm/1st h, CRP 6.1 mg/l. During the anti-inflammatory treatment, antihyperuricaemic treatment with probenecid and urine alkalisers was maintained; the level of serum uric acid remained roughly the same.

Thus, treatment with the tumour necrosis factor α (TNFα) inhibitor etanercept in a patient with a complex gouty arthritis impressively reduced the clinical manifestations of gout, and uric acid depot was depleted generally.

Figure 1 Clinical image of the right foot showing gouty arthritis with extreme swelling, erythema, and tophi.
Table 1  Monitoring disease activity (clinical and laboratory findings) under different treatment courses

<table>
<thead>
<tr>
<th>Duration of treatment</th>
<th>5 Months before anti-TNFα treatment</th>
<th>After 4th injection of etanercept</th>
<th>3 Months after beginning etanercept</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment (daily)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiphlogistic</td>
<td>Diclofenac 2×50 mg</td>
<td>Methylprednisolone 16 mg</td>
<td>Methylprednisolone 4 mg</td>
</tr>
<tr>
<td>Antiinflammatory</td>
<td>Calcinium 4–6 mg</td>
<td>Calcinium (if necessary)</td>
<td>Calcinium (if necessary)</td>
</tr>
<tr>
<td>Analgesic</td>
<td>Fluprime maleate 200 mg</td>
<td>Fentanyl 20 μg/h</td>
<td>Fentanyl 20 μg/h</td>
</tr>
<tr>
<td>Antihyperuricaemic</td>
<td>Urine alcaliser (Blemaren)</td>
<td>Urine alcaliser (Blemaren)</td>
<td>Urine alcaliser (Blemaren)</td>
</tr>
</tbody>
</table>

**Laboratory findings**

<table>
<thead>
<tr>
<th>ESR (mm/1st h)</th>
<th>CRP (mg/l)</th>
<th>WBC (×10³/l)</th>
<th>Serum uric acid (µmol/l)</th>
<th>Clinical findings</th>
<th>Number of painful joints</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td>61.0</td>
<td>9.4</td>
<td>580</td>
<td>3–4</td>
<td>12</td>
</tr>
<tr>
<td>6.1</td>
<td>6.1</td>
<td>7.4</td>
<td>580</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>&lt;5.0</td>
<td></td>
<td>5.3</td>
<td>560</td>
<td>1/month</td>
<td>2</td>
</tr>
</tbody>
</table>

Figure 2  Radiographs of the right foot showing multiple cysts, amorphous calcifications, and spikes of urate crystals in soft tissue, and destruction and erosions of bone and cartilage.

**DISCUSSION**

Effective treatment exists to prevent the complications of symptomatic hyperuricaemia. However, severe gouty arthritis together with tophaceous manifestations are rarely seen. In most cases standard treatment with colchicine, non-steroidal anti-inflammatory drugs, and moderate doses of glucocorticoids is sufficient to control the inflammation of gouty attacks. In our patient the conservative treatment of the gout, including opioids for analgesia, did not control the attacks. The use of etanercept produced a noticeable decrease in all the pathological clinical and laboratory findings (table 1).

TNFα plays an important part in different inflammatory diseases. Today, anti-TNFα is widely used in the treatment of different kinds of arthritis and primary vasculitides. Acute and chronic gouty arthritis is an inflammatory disease, in which activation of certain white blood cells occurs owing to the presence of a foreign substance—namely, urate crystals. The activation of monocytes and macrophages releases TNFα into the synovial fluid. Increased concentrations of TNFα are detectable in joints of gouty arthritis. In certain cases, gout can mimic rheumatoid arthritis. We describe the first published case of severe, recurrent tophaceous gouty arthritis refractory to anti-inflammatory treatment in a patient who was subsequently treated successfully with a TNFα inhibitor. Of particular interest is the possibility of maintaining antihyperuricaemic treatment during the antiphlogistic protection of etanercept, especially as there is a massive excavation of uric acid from the depots owing to the antihyperuricaemic treatment.

**REFERENCES**

Pyogenic sacroiliitis is a rare condition with often vague symptoms mimicking common conditions such as protruded disk, muscular strain, or visceral pain. Therefore the diagnosis is often missed or delayed. In 1986, Cohn and Schoetz reviewed patients with pyogenic sacroiliitis. In 12.6% of these cases sacroiliitis mimicked the acute abdomen. In 40–60% fever and a raised erythrocyte sedimentation rate were present. Blood cultures were positive in 60%. Magnetic resonance imaging and computer tomography can be helpful, but especially when blood cultures are negative, joint aspiration can be crucial for establishing the diagnosis. We present two cases of infectious sacroiliitis.

**CASE REPORTS**

**Patient 1**

A 19 year old woman was admitted to hospital with a 4 day history of pain in the right hip and buttock, and fever. Walking was difficult and transfers were impossible to make. Recently she had scratched the skin of her head causing some wounds. Monthly she used plugs during her menstruation. There were no abdominal complaints. She neither smoked nor used alcohol. Her medical history was unremarkable.

Examination showed a sick woman, with a temperature of 40.8°C and normal blood pressure. A general internal examination was normal. The right sacroiliac joint showed tenderness on pelvic compression without further limitations. The erythrocyte sedimentation rate was 40 mm/1st h, C reactive protein 240 mg/l, white blood cell count 8.4×10^9/l. Plain x ray examinations of chest, hip, and pelvis and ultrasonography of the hip were normal. Bone scan showed an increased uptake in the right sacroiliac joint. Magnetic resonance imaging demonstrated sacroilitis of that joint. Four blood cultures disclosed *Staphylococcus aureus*. Treatment was started with 2 weeks’ intravenous flucloxacillin 12 g daily, followed by an oral 2 week course 2 g daily. Mobility improved and she was discharged after 3 weeks. Follow up radiography showed sclerosis of the right sacroiliac joint. A year later she was still free of complaints.

**Patient 2**

A previously healthy 14 year old girl presented with acute, severe pain in the buttock radiating to the right leg and fever. Walking was difficult and transfers were impossible to make. There were no injuries or infections. Examination disclosed tenderness of the right sacroiliac joint and buttock.

A stress test of that joint was positive. Further physical examination was normal. Bearing weight on the right leg was impossible. The erythrocyte sedimentation rate was 77 mm/1st h, C reactive protein 131 mg/l, white blood cell count 12.4×10^9/l. Plain x ray examinations of chest, hip, and pelvis and ultrasonography of the hips were normal. Magnetic resonance imaging showed erosive changes of the right sacroiliac joint. Treatment was started intravenously with ciprofloxacin 200 mg twice a day for 10 days. Pain decreased and mobility improved. She was discharged after 10 days and continued oral ciprofloxacin 500 mg twice a day for 3 weeks. Three months after presentation she was mobile without pain. A follow up pelvic x ray examination showed erosive changes and sclerosis of the right sacroiliac joint.

**DISCUSSION**

Pyogenic sacroiliitis is rare, especially if caused by *Salmonella*. A review pointed to *Staphylococcus aureus* as the leading causative organism. Only 16 of the 200 cases were due to *Salmonella*. In brucellosis the sacroiliac joint was the most commonly affected osteoarticular site. *Pseudomonas* species were often found in intravenous drug abusers. Tuberculosis has usually been an indolent cause. Sacroilitis due to *Streptococcus pneumoniae* is uncommon. High suspicion of a pyogenic sacroilitis requires joint aspiration in order to establish the causative organism even if blood cultures and conventional radiography are normal.

**Authors’ affiliations**

S W Kadir, M E C Jeurissen, M J A M Franssen, Department of Rheumatology, Sint Maartenskliniek Nijmegen, Hengstdal 3, 6522 JV Nijmegen, The Netherlands

Correspondence to: Dr S W Kadir, Department of Rheumatology, Sint Maartenskliniek Nijmegen, Postbus 9011, 6500 GM Nijmegen, The Netherlands; s.kadir@maartenskliniek.nl

Accepted 2 October 2003
Use of minocycline in rheumatoid arthritis: a district general hospital experience

E Suressh, I M Morris, P C Mattingly

Double blind, randomised controlled trials have shown that minocycline is an effective disease modifying antirheumatic drug (DMARD) in rheumatoid arthritis (RA), compared with placebo or hydroxychloroquine. Minocycline was first used on the premise that RA may be caused by an infection but, subsequently, it was also shown to possess other properties such as matrix metalloproteinase inhibition and immunomodulation. Despite reported proof of its efficacy, most rheumatologists do not favour the use of minocycline in RA, possibly owing to availability of other “standard” DMARDs.

We performed a retrospective review of the case notes of 28 patients with RA who were prescribed minocycline. Treatment with minocycline in these patients began before the widespread availability of biological agents. Our aim was to assess the efficacy and safety of this drug in our hands compared with published trials. Our patients included 24 women and four men, aged between 43 and 80 years (mean 60). Their disease duration ranged from 2 to 48 years (mean 18). Rheumatoid factor status was known in 26 patients, of whom 21 were seropositive. Minocycline was used only after at least two to eight DMARDs (mean five drugs) had failed. None of these patients were receiving concomitant treatment with other DMARDs at the time of starting minocycline. We used minocycline in a dose of 100 mg twice daily.

As this was a retrospective review of case notes, improvement in disease activity could only be assessed from the information in clinic letters. Clinical improvement was assessed by factors such as improvement in joint pain and swelling, duration of early morning stiffness, function, physician’s global assessments, and general wellbeing of the patient, while improvement in laboratory measures was assessed by change in erythrocyte sedimentation rate (ESR) and haemoglobin. In the opinion of the rheumatologist the drug was considered effective in 10 (36%) patients, of whom seven were still taking it at the time of performing this study. Three of these 10 patients had to stop taking minocycline because of side effects. Benefit was noted after a mean duration of 4 months (range 2–6) and was sustained for a mean duration of 14 months (range 8–24). Stopping treatment owing to a lack of efficacy occurred in only 7/28 (25%) patients and they had taken the drug for a mean duration of 6 months (range 3–11). No differences in disease duration, number of DMARDs tried before starting minocycline, or rheumatoid factor status were found between responders and non-responders (also including patients who stopped minocycline owing to toxicity, but had received the drug for at least 4 months).

There was documented improvement in clinical measures in all patients who responded. Laboratory data were available for 24 patients, of whom 18 had taken the drug for at least 4 months (eight responders, 10 non-responders). Among the eight responders, ESR values improved by more than 40 mm/1st h in four patients (reduced to 13, 25, 31, and 31 mm/1st h), while haemoglobin improved by more than 20 g/l in two patients. We did not note any deterioration of ESR or haemoglobin values in any of the other responders. However, the ESR and haemoglobin values either remained the same or deteriorated in all non-responders save for one patient.

Thirteen (46%) patients, including the three patients in whom the drug was considered effective, stopped taking the drug because of side effects. There were no serious or long term adverse effects. The side effects that were directly attributable to minocycline included dizziness (four patients), nausea (three patients), dizziness and nausea, allergic rash, and reversible grey pigmentation (one patient each). Three patients stopped the drug owing to problems not directly related to minocycline (atrial fibrillation, allergic skin rash to trimethoprim, and non-specific chest pain). The reason for stopping minocycline was not clear from the notes for one patient.

As far as we know, no one has reported their experience with the use of minocycline in patients with RA outside a research setting. If the fact that minocycline was only tried in our patients after they had failed to respond to other DMARDs is taken into account, it can be considered as a moderately efficacious drug. Studies in future should examine the role of minocycline in early RA either on its own or as part of combination DMARD treatment.

Authors’ affiliations

E Suressh, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
I M Morris, P C Mattingly, Kettering General Hospital, Rothwell Road, Kettering NN16 8UZ, UK

Correspondence to: Dr E Suressh, Rheumatic Diseases Unit, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK; dr_esuressh@hotmail.com

Accepted 6 December 2003
Toxic myopathy induced by the ingestion of loquat leaf extract
W R Saliba, L H Goldstein, G S Habib, M S Elias

Loquat (Eriobotrya japonica) belongs to the trees of the Rosaceae family. Loquat leaves are widely used in the preparation of oriental herbal teas. In folk medicine, the loquat leaves are used against various skin diseases, cough, nausea, and itching.

Loquat leaves contain ursolic acid and oleanolic acid, which both have hypoglycaemic and antihyperlipidaemic effects in test animals. 

CASE REPORT
We present a patient with hypertriglyceridaemia, who after ingestion of loquat leaf extract had a remarkable decrease in triglycerides and an increase in high density lipoprotein (HDL). However, this benefit was accompanied by toxic myopathy, resembling the effect of HMG-CoA reductase inhibitors and fibric acid derivatives.

A 39 year old man was found to have a high fasting triglyceride level on routine blood testing. The total cholesterol level was normal, and the HDL cholesterol was low. He was otherwise healthy and smoked one packet of cigarettes a day for 5 years. He did not take any drugs, and denied habitual alcohol intake. The patient was advised to stop smoking, and he started a low fat and sugar diet.

Three months after this regimen his triglyceride level remained high (9.38 mmol/l), total cholesterol 4.30 mmol/l, and HDL 0.80 mmol/l. The patient was prescribed bezafibrate 400 mg daily. After 3 months on this regimen, the triglyceride level diminished to 3.88 mmol/l, but the creatine kinase (CK) was 1400 IU/l (6 months earlier the CK level was normal). The man had not reported myalgia; he denied fall or any trauma within the past weeks. He also denied intramuscular drug injection and strenuous exercise. Bezafibrate was stopped and the CK level returned to normal after 2 weeks.

During the following year the patient had blood tests every 2 months, the triglyceride level during this period ranged from 6.20 to 18.06 mmol/l, the total cholesterol from 3.69 to 5.10 mmol/l, the HDL from 0.80 to 1.05 mmol/l, and the CK was normal. The man refused to take lipid lowering agents, and he decided to try herbal medicines.

He had heard that an extract of loquat leaves (obtained by boiling the leaves in water) would be effective for his problem. During the following 2 weeks he drank about 2 litres daily of this extract until he presented with severe myalgia, particularly of the proximal muscles of the arms and legs. On examination he was afebrile, his body mass index was 22 kg/m². The proximal part of his limbs was tender, no erythema was detected. Blood tests showed: triglyceride 2.20 mmol/l, total cholesterol 4.50 mmol/l, HDL cholesterol 1.10 mmol/l, CK 5950 IU/l, CK 5950 IU/l, lactic dehydrogenase 412 IU/l, aspartate aminotransferase 113 IU/l, alanine aminotransferase 85 IU/l. A complete blood count, serum electrolytes, kidney, and thyroid function tests were normal. An electrocardiogram showed sinus rhythm without signs of ischaemia.

The patient was admitted and treated with intravenous fluids. On the third day the transaminases returned to normal, the CK level decreased to 1102 IU/l, and the patient was discharged. Blood tests taken after 2 weeks showed a normal CK level and a triglyceride level of 4.14 mmol/l. During the following 5 months the patient underwent three blood tests that showed a triglyceride level of 4.74–10.18 mmol/l and an HDL level of 0.85–1.00 mmol/l; he decided to take the loquat leaf extract at reduced doses. Blood tests taken three weeks later showed: triglyceride 1.98 mmol/l, HDL 1.15 mmol/l, and CK 1330 IU/l; the transaminases were normal.

DISCUSSION
The decreased triglyceride level, in addition to the myopathy, represented by myalgia and a rise in CK, in the absence of other apparent causes, strongly suggests that these effects are related to the ingestion of loquat leaf extract. This assumption is supported by the recurrence of the same effects after rechallenge by the patient himself. Whether the antihyperlipidaemic effect and toxic myopathy are related to the action of one or more constituents of the loquat leaves is not clear.

Only a minority of patients develop myopathy in response to lipid lowering agents,++ with an incidence ranging from 0.1 to 0.5%. There are strong indications that other (endocrine, metabolic, genetic) factors may have a role in the pathophysiology of the myopathy. In our patient the CK level increased significantly after 3 months’ treatment with bezafibrate. This patient might have been particularly sensitive to this type of treatment, and may have a predisposing factor, probably genetic.

The pronounced difference of CK level on the two occasions after ingestion of loquat leaf extract, suggests that this extract has a dose dependent toxic effect. However, this toxic effect may occur only in predisposed patients as is the case for myopathy related to lipid lowering agents.

Ingestion of loquat leaves should be included in the differential diagnosis of myopathy. The potential effect of

REFERENCES
loquat leaves to lower triglyceride and increase HDL levels merits further investigation.

---

**Authors’ affiliations**

W R Saliba, H Goldstein, M S Elias, Department of Medicine C, HaEmek Medical Centre, affiliated to the Technion-Israel Institute of Technology, Faculty of Medicine, Afula, 18101, Israel

G S Habib, Department of Medicine B, Lady Davis Medical Centre, affiliated to the Technion-Israel Institute of Technology, Faculty of Medicine, Haifa, Israel

Correspondence to: Dr W R Saliba; salibuss@yahoo.com

Accepted 6 December 2003

---

**REFERENCES**


---

**Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement**

K Minden, E Aganna, M F McDermott, A Zink

---

Tumour necrosis factor receptor associated periodic syndrome (TRAPS) is an autosomal dominant disorder resulting from mutations in the TNFRSF1A gene, characterised by recurrent attacks of fever, abdominal pain, severe myalgia, skin rashes, conjunctivitis, and/or periorbital oedema. These symptoms, which are partially explained by the unopposed action of tumour necrosis factor (TNF) owing to decreased soluble TNF receptor 1 (sTNFRSF1A) serum levels, can be alleviated by administration of etanercept, which is a TNFRSF1B (TNFR2) p75:Fc fusion protein. We describe a family in which one of three affected members with central nervous system (CNS) symptoms developed a demyelinating disorder suspected to be a feature of TRAPS.

**CASE REPORT**

A 20 year old white man and his 25 year old sister had complained about recurrent attacks of fever, abdominal and loin pain, severe myalgia, skin lesions, sore throat, conjunctivitis, and periorbital oedema since early childhood. These attacks had come at irregular intervals, lasted for 2–3 weeks, and were accompanied by greatly increased acute phase reactants. During childhood both patients had received long term steroid treatment, which partially alleviated the symptoms; in addition, they had been treated with multiple immunosuppressive drugs (for example, chlorambucil, azathioprine, methotrexate) without any detectable benefit, under the erroneous impression they had Still’s disease.

The young man developed depressive symptoms without other signs of a neurological disease in his teens, while his sister experienced a neurological illness with dizziness and paraesthesia in her hands, feet, and around the umbilical area at the age of 22. At that time, conventional T2 weighted magnetic resonance imaging (MRI) of the brain disclosed multiple small hyperintense lesions (most were <6 mm), located in the supratentorial white matter, and some of which showed gadolinium enhancement on T1 weighted, spin echo sequences. The location of these lesions was not typical of multiple sclerosis; cerebrospinal fluid analysis showed pleocytosis and oligoclonal bands, while electroencephalography, visual and somatosensory evoked potentials, selective digital subtraction angiography, and a neurological examination were all normal.

The father of both siblings had also had periodic fevers in childhood, progressing in adulthood to intense localised muscle pain and profound stiffness, associated with depressive symptoms, memory impairment, and recurrent loss of sensation and power in his fingertips and hands. Both the clinical examination by a neurologist and the electromyography/neuropathy pointed to a myotonic disorder.

All three affected family members have a T50K mutation in exon 3 of the TNFRSF1A gene with associated low sTNFRSF1A levels; defective shedding of TNFRSF1A was demonstrated in the young man’s peripheral blood mononuclear cells on FACS analysis. Given the severity of attacks in both siblings, treatment with etanercept was started, which dramatically improved both patients’ wellbeing, with normalisation of laboratory values. An improvement in paraesthesia without further changes of the MRI findings occurred in the woman during the initial months of anti-TNF treatment. However, at month 20 of etanercept treatment unilateral optic neuritis developed and, compared with imaging performed 12 months previously, new demyelinating lesions were detected by fluid attenuated inversion recovery (FLAIR) MRI (fig 1). This clinical exacerbation occurred in what appeared to be the setting of a TRAPS flare, because fever, arthralgia, muscle stiffness, skin and eye lesions occurred concomitantly.

**DISCUSSION**

As increased TNF/TNFR signalling has a key role in TRAPS, and is also implicated in inflammatory demyelinating disease of the CNS, one may speculate that the CNS symptoms seen in the young woman are part of the TRAPS phenotype. This is supported by other reports of CNS symptoms in TRAPS, including a severe neurological illness in a woman with a T50M mutation, optic neuritis/papillitis in a woman with a C30R mutation, and behavioural changes in a man and his daughter with the R92Q variant. Whether the CNS symptoms in the woman’s brother and father, however, were also...
due to white matter disease is unknown, because imaging of the brain was not carried out in either of them and the presence of white matter disease was not proved conclusively by other examinations.

Etanercept has been shown to alleviate symptoms in about two thirds of patients with TRAPS, but it did not impede progression of the demyelinating disorder in this young woman. It remains unclear whether exacerbation of her neurological symptoms was an integral part of the disease flare or due to TNF antagonist treatment, as occasionally seen in patients with multiple sclerosis. Notably, another patient with TRAPS (T50M mutation) has also experienced paraesthesias and altered cognition while receiving etanercept (Hull K, personal communication).

Further research is necessary to verify whether CNS symptoms are part of the TRAPS phenotype or whether patients with TRAPS carry a particular risk of developing neurological complications owing to TNF antagonism. Meanwhile, clinicians should be aware of possible CNS involvement in TRAPS, with close monitoring of those patients receiving etanercept.

Accepted 19 November 2003

REFERENCES

Toxic myopathy induced by the ingestion of loquat leaf extract

W R Saliba, L H Goldstein, G S Habib and M S Elias

*Ann Rheum Dis* 2004 63: 1355-1356
doi: 10.1136/ard.2003.016790